Literature DB >> 22237965

What do cytokine profiles tell us about subsets of juvenile idiopathic arthritis?

Rolando Cimaz1, Davide Moretti, Ilaria Pagnini, Achille Marino, Luca Cantarini, Gabriele Simonini.   

Abstract

Classification of juvenile idiopathic arthritis is an ongoing process and up to now has been predominantly based on clinical manifestations--mainly number of joints at onset of disease. In the meantime, basic studies have advanced our knowledge regarding the disease pathogenesis. Unfortunately, studies of cytokines and cytokine polymorphisms have not followed the predominantly clinical International League of Associations for Rheumatology classification in that no significant biological differences among the different disease categories have been demonstrated with robust associations. Only systemic-onset disease seems to be quite different from other disease categories with regard to biologic mechanisms; indeed, it now seems closer to autoinflammatory than to classic autoimmune diseases. New players in the immunologic basis of juvenile idiopathic arthritis (eg, interleukin-17 and regulatory T cells) are also discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237965     DOI: 10.1007/s11926-011-0233-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  27 in total

1.  Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis.

Authors:  Masaki Shimizu; Tadafumi Yokoyama; Keiko Yamada; Hisashi Kaneda; Hideo Wada; Taizo Wada; Tomoko Toma; Kazuhide Ohta; Yoshihito Kasahara; Akihiro Yachie
Journal:  Rheumatology (Oxford)       Date:  2010-05-14       Impact factor: 7.580

2.  Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.

Authors:  Thomas A Griffin; Michael G Barnes; Norman T Ilowite; Judyann C Olson; David D Sherry; Beth S Gottlieb; Bruce J Aronow; Paul Pavlidis; Claas H Hinze; Sherry Thornton; Susan D Thompson; Alexei A Grom; Robert A Colbert; David N Glass
Journal:  Arthritis Rheum       Date:  2009-07

3.  IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA).

Authors:  J C Möller; D Paul; G Ganser; U Range; M Gahr; R Kelsch; A Rösen-Wolff; C M Hedrich
Journal:  Clin Exp Rheumatol       Date:  2011-01-04       Impact factor: 4.473

4.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Authors:  Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Shuji Takei; Naomi Iwata; Hiroaki Umebayashi; Takuji Murata; Mari Miyoshi; Minako Tomiita; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

5.  Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis.

Authors:  Marija Jelusić; Ivan Kresimir Lukić; Lana Tambić-Bukovac; Klara Dubravcić; Ivan Malcić; Igor Rudan; Drago Batinić
Journal:  Clin Rheumatol       Date:  2006-11-25       Impact factor: 2.980

6.  Th17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis.

Authors:  Biagio Olivito; Gabriele Simonini; Sara Ciullini; Maria Moriondo; Letizia Betti; Eleonora Gambineri; Luca Cantarini; Maurizio De Martino; Chiara Azzari; Rolando Cimaz
Journal:  J Rheumatol       Date:  2009-07-31       Impact factor: 4.666

7.  CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.

Authors:  Ismé M de Kleer; Lucy R Wedderburn; Leonie S Taams; Alka Patel; Hemlata Varsani; Mark Klein; Wilco de Jager; Gisela Pugayung; Francesca Giannoni; Ger Rijkers; Salvatore Albani; Wietse Kuis; Berent Prakken
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

Review 8.  Oligoarticular and polyarticular JIA: epidemiology and pathogenesis.

Authors:  Claudia Macaubas; Khoa Nguyen; Diana Milojevic; Jane L Park; Elizabeth D Mellins
Journal:  Nat Rev Rheumatol       Date:  2009-10-06       Impact factor: 20.543

9.  A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).

Authors:  Pierre Quartier; Florence Allantaz; Rolando Cimaz; Pascal Pillet; Claude Messiaen; Christophe Bardin; Xavier Bossuyt; Anne Boutten; Jacques Bienvenu; Agnes Duquesne; Olivier Richer; Damien Chaussabel; Agnes Mogenet; Jacques Banchereau; Jean-Marc Treluyer; Paul Landais; Virginia Pascual
Journal:  Ann Rheum Dis       Date:  2010-12-20       Impact factor: 19.103

10.  Novel IL10 gene family associations with systemic juvenile idiopathic arthritis.

Authors:  Mark S Fife; Ana Gutierrez; Emma M Ogilvie; Carmel J W Stock; Jane M Samuel; Wendy Thomson; Lisa F Mack; Cathryn M Lewis; Patricia Woo
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  2 in total

1.  The profile of polyunsaturated fatty acids in juvenile idiopathic arthritis and association with disease activity.

Authors:  Daiva Gorczyca; Jacek Postępski; Aleksandra Czajkowska; Mariola Paściak; Anna Prescha; Edyta Olesińska; Anna Gruenpeter; Iwona Lachór-Motyka; Bogumiła Szponar
Journal:  Clin Rheumatol       Date:  2017-02-28       Impact factor: 2.980

2.  Interleukin-17A Levels Increase in Serum of Children With Juvenile Idiopathic Arthritis.

Authors:  Gordana Vijatov-Djuric; Aleksandra Doronjski; Igor Mitic; Snezana Brkic; Nenad Barisic
Journal:  Arch Rheumatol       Date:  2017-04-04       Impact factor: 1.472

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.